The estimated Net Worth of Research Corp Acacia is at least $51.3 Milione dollars as of 4 June 2020. Research Acacia owns over 9,138,504 units of Evofem Biosciences Inc stock worth over $9 and over the last 8 years Research sold EVFM stock worth over $51,267,338.
Sign up
Research Acacia EVFM stock SEC Form 4 insiders trading
Research has made over 7 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Research sold 9,138,504 units of EVFM stock worth $29,334,598 on 4 June 2020.
The largest trade Research's ever made was selling 9,138,504 units of Evofem Biosciences Inc stock on 4 June 2020 worth over $29,334,598. On average, Research trades about 1,618,419 units every 81 days since 2017. As of 4 June 2020 Research still owns at least 1,000 units of Evofem Biosciences Inc stock.
You can see the complete history of Research Acacia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Research Acacia's mailing address?
Research's mailing address filed with the SEC is 4 PARK PLAZA, SUITE 550, IRVINE, CA, 92614.
Insiders trading at Evofem Biosciences Inc
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link e Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
What does Evofem Biosciences Inc do?
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
What does Evofem Biosciences Inc's logo look like?
Complete history of Research Acacia stock trades at Veritone Inc, Drive Shack Inc e Evofem Biosciences Inc
Evofem Biosciences Inc executives and stock owners
Evofem Biosciences Inc executives and other stock owners filed with the SEC include:
-
Saundra Pelletier,
President, Chief Executive Officer, Director -
Kelly Culwell,
Chief Medical Officer -
Saundra Pelletier,
Pres, CEO & Director -
Thomas Lynch,
Chairman of the Board -
Russell Barrans,
Chief Commercial Officer -
Justin File,
Chief Financial Officer -
Justin J. File,
Chief Financial Officer -
Russell Barrans,
Chief Commercial Officer -
Tony O'Brien,
Independent Director -
William Hall,
Independent Director -
Colin Rutherford,
Independent Director -
Gillian Greer,
Independent Director -
Kim Kamdar,
Independent Director -
Amy Raskopf,
IR Contact Officer -
Lisa Rarick,
Independent Director -
Alexander Fitzpatrick,
Executive Vice President, General Counsel, Secretary -
Dr. Kelly Culwell M.D.,
Chief Medical Officer -
Kathy Gallo-Doyle,
VP of Sales -
Alexander A. Fitzpatrick Esq.,
Exec. VP, Gen. Counsel & Sec. -
Biopharma, Inc. Pdl,
10% owner -
Research Corp Acacia,
10% owner -
Anthony Stephen O'brien,
Director -
Yan Zhang,
CFO -
Ltd. Invesco,
10% owner -
Fund Solutions Ltd Link,
10% owner